New Clinical Trial Partners to Expand Laboratory Sciences Clinical Sample Analysis Groups - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Clinical Trial Partners to Expand Laboratory Sciences Clinical Sample Analysis Groups



Charles River has established partnerships with Target Health Inc. and Theorem Clinical Research Inc. allow nonclinical testing programs performed by Charles River in bioanalysis, immunogenicity, and immunology to transition to support clinical trials.

Charles River develops and validates assays in support of nonclinical programs. Many of these assays can be transferred and validated for human matrix and subsequently used for analyzing clinical samples.

In a statement, the Charles River reports that these new relationships will allow company scientists to manage clinical sample analysis using defined processes and procedures to improve customer satisfaction.

http://www.criver.com

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here